REFERENCES
1. Ose L. Müller-harbitz disease--familial hypercholesterolemia. Tidsskr Nor Laegeforen. 2002;122:924-5.
2. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34-47.
3. Taranto MD, Fortunato G. Genetic heterogeneity of familial hypercholesterolemia: repercussions for molecular diagnosis. Int J Mol Sci. 2023;24:3224.
4. Thompson GR, Blom DJ, Marais AD, Seed M, Pilcher GJ, Raal FJ. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J. 2018;39:1162-8.
5. Blom DJ, Byrnes P, Jones S, Marais AD. Non-denaturing polyacrylamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinemia. J Lipid Res. 2003;44:212-7.
6. Phatlhane DV, Zemlin AE. Severe hypercholesterolemia mediated by lipoprotein X in a patient with cholestasis. Ann Hepatol. 2015;14:924-8.
7. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet. 1969;2:1380-2.
8. Firth JC, Marais AD. Familial hypercholesterolaemia: the Cape Town experience. S Afr Med J. 2008;98:99-104.
9. Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet. 2013;381:1293-301.
10. Minchiotti L, Caridi G, Campagnoli M, Lugani F, Galliano M, Kragh-Hansen U. Diagnosis, phenotype, and molecular genetics of congenital Analbuminemia. Front Genet. 2019;10:336.
11. Bashir A, Tiwari P, Duseja A. Enzyme replacement therapy in lysosomal acid lipase deficiency (LAL-D): a systematic literature review. Ther Adv Rare Dis. 2021;2:26330040211026928.
12. D’Erasmo L, Di Costanzo A, Arca M. Autosomal recessive hypercholesterolemia: update for 2020. Curr Opin Lipidol. 2020;31:56-61.
13. Windler E, Beil FU, Berthold HK, et al. Phytosterols and cardiovascular risk evaluated against the background of phytosterolemia cases-a German expert panel statement. Nutrients. 2023;15:828.
14. Fellin R, Manzato E. Lipoprotein-X fifty years after its original discovery. Nutr Metab Cardiovasc Dis. 2019;29:4-8.
15. Stelten BML, Raal FJ, Marais AD, et al. Cerebrotendinous xanthomatosis without neurological involvement. J Intern Med. 2021;290:1039-47.
16. Marais AD. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. Pathology. 2019;51:165-76.
17. Wilemon KA, Patel J, Aguilar-Salinas C, et al. Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action. JAMA Cardiol. 2020;5:217-29.
18. Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J. 1967;41:1271-4.
19. Seftel HC, Baker SG, Sandler MP, et al. A host of hypercholesterolaemic homozygotes in South Africa. Br Med J. 1980;281:633-6.
20. Gevers W. Three mutations that cause familial hypercholesterolemia in Afrikaners identified-a milestone in South African medicine. S Afr Med J. 1989;76:393-4.
21. Marais AD, Firth JC, Rose AG, Berger GM. Fatal outcome of homozygous familial hypercholesterolaemia in a black patient. A case report. S Afr Med J. 1990;77:588-90.
22. Marais AD, Berger GMB. A diversity of genetic hyperlipoproteinaemias in black patients. Experience at the lipid clinics at Groote Schuur hospital and red cross war memorial children's hospital, Cape Town. S Afr Med J. 1986;70:583-7.
23. Langenhoven E, Warnich L, Thiart R, et al. Two novel point mutations causing receptor-negative familial hypercholesterolemia in a South African Indian homozygote. Atherosclerosis. 1996;125:111-9.
24. Marais AD, Naoumova RP, Firth JC, Penny C, Neuwirth CKY, Thompson GR. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res. 1997;38:2071-8.
25. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ. 1992;304:431-4.
26. Marais AD, Benatar SR. Planning rational management of chronic diseases-lessons from a lipid clinic. S Afr Med J. 1995;85:340-1.
28. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111-88.
29. Klug EQ, Raal FJ, Marais AD, et al. South African dyslipidaemia guideline consensus statement: 2018 update A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA). S Afr Med J. 2018;108:973-1000.
30. Klug QE, Raal FJ. Heart groups in South Africa advocate for tighter LDL-C control and lipoprotein(a) testing to curb atherosclerotic cardiovascular disease. S Afr Med J. 2024;114:e1973.
32. Marais AD, Blom DJ, Raal FJ. Response to: prescribed minimum benefits complaints: a 5-year retrospective review. S Afr Med J. 2024;114:e2450.
34. Marais AD, Blom DJ, Raal FJ; On Behalf Of The Lipid And The Lipid And Atherosclerosis Society Of Southern Africa. Familial hypercholesterolaemia in South Africa: a reminder. S Afr Med J. 2021;111:700-1.
35. South African Government. National Health Laboratory Service Act 37 of 2000. Republic of South Africa. Available from:https://www.gov.za/documents/national-health-laboratory-service-act [Last accessed on 18 JuL 2025].
36. Marais AD. Familial hypercholesterolaemia and genetic dyslipidaemia: opportunities and needs in management as seen from South Africa. Data presented at the ISA 2012 Satellite Meeting of the International Atherosclerosis Society, Sydney, Australia. 2012.
